Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Open Label Dose-ranging Study of Sepantronium Bromide in Patients With Relapsed/Refractory c-Myc Rearranged High-grade B-cell Lymphoma (HGBCL)

NCT05263583 is registered in ClinicalTrials.gov with Cothera Bioscience, Inc as lead sponsor.

NCT NCT05263583
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05263583 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Open Label Dose-ranging Study of Sepantronium Bromide in Patients With Relapsed/Refractory c-Myc Rearranged High-grade B-cell Lymphoma (HGBCL)
Lead sponsor
Cothera Bioscience, Inc
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 9, 2022
Completion date
June 30, 2025
Enrollment
14 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

burkitt lymphoma, c-myc gene rearrangement, c-myc/bcl2 double-hit high-grade b-cell lymphoma, c-myc/bcl6 double-hit high-grade b-cell lymphoma, high-grade b-cell lymphoma, lymphatic diseases, lymphoma, b-cell, lymphoma, high-grade, lymphoma, large b-cell, diffuse